Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units
Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year
502 active customers as of
Company made substantial progress toward FDA clearance and planned market expansion during the year
"Fiscal 2026 was a year of clear, compounding progress across every aspect of our business," said
"The financial results for fiscal 2026 reflect a business that is scaling with improving unit economics," said Spiro Sakiris, CFO at Intelligent Bio Solutions. "Full-year gross profit grew 64% to
Full Year Fiscal 2026 Financial Highlights
- Total revenue of
$4,215,175 , up 38% year-over-year from$3,052,532 . - Revenue increase of
$1,162,643 year-over-year. - Gross profit of
$2,049,994 , up 64% year-over-year from$1,246,859 . - Gross profit margin of 48.63%, up from 40.85% - an improvement of 778 basis points.
- Reader installed base of 1,886 units as of
June 30, 2026 , up 22% from 1,545 units as ofJune 30, 2025 . - Total consumable cartridges of 106,500 units, up 35% from 78,750 in fiscal 2025.
- 502 active customers as of
June 30, 2026 .
Progress Toward FDA Clearance and U.S. Market Expansion
INBS made substantial progress throughout fiscal 2026 in advancing its FDA 510(k) submission, supporting its planned entry into the multi-billion-dollar
- Initiated and completed a clinical cut-off study evaluating codeine detection cut-off levels in 40 adults, advancing the clinical evidence base for the 510(k) program.
- Completed penetration testing, with no major vulnerabilities identified, strengthening the cybersecurity component of the submission package.
- Initiated a multi-site method comparison study, designed to evaluate system accuracy when operated by intended end-users. The study was completed in early fiscal 2027.
- Initiated an interference study examining the impact of everyday substances on the Intelligent Fingerprinting Drug Screening System. The study was completed in early fiscal 2027.
- Initiated precision testing, evaluating reproducibility across varied manufacturing conditions and operating environments. The study was completed in early fiscal 2027, confirming reproducibility across more than 1,600 tests, three production runs, and three independent testing sites.
- Initiated a usability study designed to evaluate how effectively operators could be trained to use the Intelligent Fingerprinting Drug Screening System. The study was completed in early fiscal 2027.
- Initiated validation study for a rapid drug screening cartridge targeting 70% faster results.
- Strengthened the Company's European intellectual property portfolio with its eighth patent grant, further protecting its proprietary fingerprint drug screening technology.
- The Company's FDA 510(k) submission is on track for the second half of calendar 2026, progressing toward planned entry into the U.S. market, the world's largest drug screening market.
Commercial Growth and Market Expansion
INBS continued to expand its commercial presence across international markets throughout fiscal 2026, supported by targeted investment in marketing, sales, and customer support infrastructure.
- Active customer base grew to 502 accounts as of
June 30, 2026 . - Reader installed base expanded 22% to 1,886 units, with each new placement creating the recurring consumable demand that underpins the Company's revenue model.
- Total consumable cartridges grew 35% to 106,500 units, outpacing the rate of installed base growth and confirming deepening utilization among existing customers.
- Commercial traction extended across safety-critical sectors including construction, manufacturing, transport and logistics, and mining, with continued growth across the
UK ,Europe , APAC, and theMiddle East . - Strategic partnership secured with
Bouygues UK , part of global construction groupBouygues Construction , for a drug-testing rollout, adding a significant new customer in a high-profile, safety-critical environment. - Strategic manufacturing transition to Syrma Johari, a high-quality, lower-cost manufacturing partner, with initial production runs successfully completed and shipments underway. This partnership is delivering a significant reduction in manufacturing costs, directly contributing to gross margin expansion.
Operational Efficiencies Strengthening Business Fundamentals
The improvement in gross profit margin from 40.85% to 48.63% year-over-year reflects the structural progress INBS has made in its production and commercial operations throughout fiscal 2026:
- The transition of reader manufacturing is expected to be transformational for the Company's cost structure and is expected to support long-term margin improvement. This positions INBS to achieve materially stronger unit economics as the installed base and production volumes continue to grow.
- Increasing economies of scale in manufacturing and distribution as production volumes grew.
- Continued optimization of product mix, with higher-margin cartridge consumables representing a growing proportion of total revenue.
- Increased investment in customer support, contributing directly to higher consumables utilization rates across the installed base and reinforcing recurring revenue generation.
About Intelligent Bio Solutions Inc.?
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit:?https://ibs.inc/?
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, secure regulatory clearance or approvals, and timelines to enter the U.S. market, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.?
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director?
KCSA Strategic Communications?
PH: (212) 896-1254?
INBS@kcsa.com
-- Financial tables to follow --
Consolidated Balance Sheets | ||||||||
| As of | As of | |||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 3,992,312 | $ | 1,019,909 | ||||
| Accounts receivable, net | 848,464 | 594,614 | ||||||
| Inventories, net | 418,577 | 635,215 | ||||||
| Research and development tax incentive receivable | 806,951 | 734,408 | ||||||
| Assets held for sale | - | 327,500 | ||||||
| Prepaid expenses and other current assets | 1,030,932 | 826,976 | ||||||
| Total current assets | 7,097,236 | 4,138,622 | ||||||
| Property and equipment, net | 294,399 | 251,325 | ||||||
| Operating lease right-of-use assets | 1,751,040 | 69,520 | ||||||
| Intangibles, net | 2,799,161 | 3,790,319 | ||||||
| Total assets | $ | 11,941,836 | $ | 8,249,786 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 4,130,213 | $ | 4,534,246 | ||||
| Current portion of operating lease liabilities | 147,005 | 84,659 | ||||||
| Current employee benefit liabilities | 651,706 | 534,990 | ||||||
| Notes payable | - | 197,146 | ||||||
| Total current liabilities | 4,928,924 | 5,351,041 | ||||||
| Employee benefit liabilities, less current portion | 49,931 | 84,921 | ||||||
| Operating lease liabilities, less current portion | 1,672,155 | - | ||||||
| Total liabilities | 6,651,010 | 5,435,962 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity | ||||||||
| Common stock, | 29,056 | 7,324 | ||||||
| (1 | ) | (1 | ) | |||||
| Additional paid-in capital* | 80,992,006 | 65,849,822 | ||||||
| Accumulated deficit | (74,964,040 | ) | (62,533,065 | ) | ||||
| Accumulated other comprehensive loss | (546,186 | ) | (327,944 | ) | ||||
| Total consolidated | 5,510,835 | 2,996,136 | ||||||
| Non-controlling interest | (220,009 | ) | (182,312 | ) | ||||
| Total shareholders’ equity | 5,290,826 | 2,813,824 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 11,941,836 | $ | 8,249,786 | ||||
| * | Common stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on |
Consolidated Statements of Operations and Other Comprehensive Income (Loss) | ||||||||
| Year ended | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | 4,215,175 | $ | 3,052,532 | ||||
| Cost of revenue (exclusive of amortization shown separately below) | (2,165,181 | ) | (1,805,673 | ) | ||||
| Gross profit | 2,049,994 | 1,246,859 | ||||||
| Other income | ||||||||
| Government support income | 677,776 | 816,901 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative expenses | (10,502,161 | ) | (8,918,468 | ) | ||||
| Development and regulatory approval expenses | (3,371,292 | ) | (2,396,513 | ) | ||||
| Depreciation and amortization | (1,163,847 | ) | (1,207,875 | ) | ||||
| Impairment of long-lived assets | (298,555 | ) | (220,062 | ) | ||||
| Total operating expenses | (15,335,855 | ) | (12,742,918 | ) | ||||
| Loss from operations | (12,608,085 | ) | (10,679,158 | ) | ||||
| Other income (expense), net | ||||||||
| Interest expense | (10,736 | ) | (26,339 | ) | ||||
| Realized foreign exchange gain (loss) | 39,820 | (911 | ) | |||||
| Interest income | 110,329 | 101,522 | ||||||
| Total other income, net | 139,413 | 74,272 | ||||||
| Net loss | (12,468,672 | ) | (10,604,886 | ) | ||||
| Net loss attributable to non-controlling interest | (37,697 | ) | (36,153 | ) | ||||
| Net loss attributable to | $ | (12,430,975 | ) | $ | (10,568,733 | ) | ||
| Other comprehensive (loss) income | ||||||||
| Foreign currency translation (loss) gain | (218,242 | ) | 384,670 | |||||
| Total other comprehensive (loss) income | (218,242 | ) | 384,670 | |||||
| Comprehensive loss | (12,686,914 | ) | (10,220,216 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | (37,697 | ) | (36,153 | ) | ||||
| Comprehensive loss attributable to | $ | (12,649,217 | ) | $ | (10,184,063 | ) | ||
| Net loss per share, basic and diluted* | $ | (8.44 | ) | $ | (20.04 | ) | ||
| Weighted average shares outstanding, basic and diluted* | 1,472,744 | 527,364 | ||||||
| * | Common stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on |
